Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group CO.17 - A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Carcinoma

Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: Canadian Cancer Trials Group/AGITG CO.17 (ONLINE). Ann Oncol 2012.

Cetuximab-induced hypomagnesemia has been associated with improved clinical outcomes in advanced colorectal cancer. The authors explored this relationship from Canadian Cancer Trials Group CO.17 and found that in contrast to prior reports, cetuximab-induced hypomagnesemia was associated with poor overall survival, even after adjustment for grade of rash.

http://annonc.oxfordjournals.org/content/early/2012/11/08/annonc.mds577.abstract

________________________________________

Canadian Cancer Trials Group SR.3 (EORTC 62931) - Randomized Phase III Trial of Adjuvant Chemotherapy with High-Dose Doxorubicin Ifosfamide and Lenograstim in High Grade Soft Tissue Sarcoma

Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. The Lancet Oncology 13: 1045-54, 2012.

Results of the trial show that adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival. The authors suggest that future studies should focus on patients with larger, grade III, and extremity sarcomas.

http://www.sciencedirect.com/science/article/pii/S1470204512703467